This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Hisamitsu America Inc.
Hisamitsu America Inc., a subsidiary of Hisamitsu Pharmaceutical Co., Inc., is headquartered in the United States and operates primarily in the healthcare and pharmaceutical industry. Founded in 1985, the company has established itself as a leader in transdermal patch technology, particularly known for its flagship product, Salonpas, which offers effective pain relief through innovative formulations. With a strong presence across North America, Hisamitsu America focuses on providing high-quality topical analgesics and other healthcare solutions. The company’s commitment to research and development has led to significant advancements in pain management, making its products unique in their efficacy and convenience. Hisamitsu America continues to strengthen its market position, recognised for its dedication to improving the quality of life for individuals suffering from pain.
DitchCarbon Score
How does Hisamitsu America Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisamitsu America Inc.'s score of 30 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hisamitsu America Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Hisamitsu Pharmaceutical Co., Inc., which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Hisamitsu America Inc. However, emissions data and performance metrics may be inherited from its parent company, Hisamitsu Pharmaceutical Co., Inc., which operates under various sustainability initiatives, including participation in the CDP (formerly Carbon Disclosure Project). This relationship suggests that Hisamitsu America Inc. may align its climate strategies with those of its parent company, although specific figures or targets have not been disclosed. In summary, while Hisamitsu America Inc. does not currently report its own emissions data or reduction targets, it is positioned within a corporate family that may influence its climate commitments through inherited practices and initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,986,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,919,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 100,228,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hisamitsu America Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
